6534-28-7

Usage

Uses

Used in Paint Industry:
1,4-Diacetamidoanthraquinone is used as a blue pigment for its good lightfastness and thermal stability, making it suitable for outdoor applications and ensuring the longevity and vibrancy of painted surfaces.
Used in Ink Industry:
As a blue pigment in inks, 1,4-Diacetamidoanthraquinone provides excellent color strength and resistance to migration, ensuring consistent color quality in printed materials.
Used in Plastics Industry:
1,4-Diacetamidoanthraquinone is used in the production of colored plastics, offering good lightfastness and thermal stability to maintain the color and integrity of plastic products over time.
However, it is important to note that 1,4-Diacetamidoanthraquinone may have certain health and environmental risks associated with its use. Therefore, proper handling and disposal procedures should be followed to minimize potential hazards.

Upstream product

• 128-95-0 1,4-diamino-9,10-anthraquinone 
• 108-24-7 acetic anhydride 
• 6937-74-2 1-amino-4-nitroanthraquinone 
• 82-45-1 1-amino-9,10-anthracenedione 
• 73840-77-4 N-(9,10-dioxo-9,10-dihydro-1-anthryl)oxamic acid 
• 75-36-5 acetyl chloride 
• 64-19-7 acetic acid 

Downstream Products

• 93858-05-0 1,4-bis-acetylamino-2-nitro-anthraquinone 
• 128-95-0 1,4-diamino-9,10-anthraquinone 
• 23677-62-5 1,4-diamino-2-nitro-anthraquinone 
• 82-33-7 1,4-diamino-5-nitroanthraquinone 
• 6471-02-9 1-amino-4-acetylamino-9,10-anthraquinone 

Relevant academic research and scientific papers

Synthesis and pharmaceuticals of novel bis-substituted anthraquinone derivatives

This invention relates to novel anthraquinone compounds useful in the treatment of allergic, inflammatory conditions, antioxidant, tumor condition, stem cell application, tissue engineering, applied in treating age-associate tissue degeneration, reverse organ failure in chronic high-turnover disease and therapeutic compositions containing such compounds. The compounds of the present invention are 1,4-, 1,5- and 1,8-difunctionalized anthraquinones or analogs thereof. According to the practice of the invention, there are provided bis-symmetrical substituted anthraquinone compounds according to formula I: wherein R1, R2, R3 and R4 present a straight, aminoalkylamino side chains or branched chain alkyl group having 1 to 6 carbons which may be substituted with one or more groups of R5, or R1, R2, R3 and R4 present phenyl or benzyl which may be substituted with one or two groups of R6; wherein R5 is selected from the group consisting of halogen, —RNH2, —RNH2R, —ROH, —NO2, —OCH3, —OCH2CH3, and —OCH2CH2CH3; and wherein R6 is selected from the group consisting of a straight or branched chain alkyl group having 1 to 4 carbons, halogen, —RNH2, —RNH2R, —ROH, —NO2, —OCH3, —OCH2CH3, —OCH2CH2CH3, —CH2Br, —CH2Cl, —CH2OH, —C(CH3)3, —(CH2)20H, —(CH2)3OH, —(CH2)4OH, —CH2NH2, —(CH2)2NH2, —(CH2)3NH2, —(CH2)4NH2, —(CH2)5NH2, —CH2N(CH3)2, —(CH2)2N(CH3)2, —(CH2)2NH(CH2)2OH, —(CH2)3NH(CH2)2OH, —(CH2)2NHCH2OH, —(CH2)3NHCH2OH, —CH2CH(CH3)2, —CHCl2, —CH(CH3)Cl, —(CH2)2Cl, —(CH2)3Cl, —(CH2)3Br, —(CH2)4Br, and —(CH2)4Cl. Chart 1. Activation of hTERT promoter-driven SEAP expression by c-Myc. About 1×107 hTERT-BJ1 cells were transfected with 13.5 μg each of plasmid pSEAP or pPhTERT-SEAP and of plasmid pMT2T or pMT2T-cMyc by electroporation. After 24 h, viable cells were harvested, and reinoculated at a density of 3×105/mL, and the SEAP activity after 24 h at 37 □. The transfection efficiency of each experiment was determined by cotransfection with 1.5 μg of plasmid pCMVβ. The values were determined from three experiments. P0.05 is presented by an asterisk.

Synthesis and structure-activity correlations of the cytotoxic bifunctional 1,4-diamidoanthraquinone derivatives

Anthraquinone-based compounds are attractive target for the design of new anticancer drugs. We have previously described a series of 1,5- and 1,4-difunctionalized anthraquinones, which exhibit different spectra of potency, together with human telomerase evaluation. The present study details the preparation of further, distinct series of regioisomeric difunctionalized amidoanthraquinone and examines their in vitro cytotoxicity in C6, Hepa G2, and 2.2.15 cell lines. Two structurally related compounds, mitoxantrone and adriamycin, were tested in parallel as positive controls. The structure-activity relationships indicated amido substitution may lead to a different mechanism of cytotoxicity. Compounds, which have -(CH2)n- side chains terminating in basic groups such as aminoalkyl-substituted, showed cytotoxic activity in several cell lines. The exact mode of intercalative binding may be dictated by the positional placement of substituent side chains. Implications for amidoanthraquinone cytotoxicity as potential anticancer agents are discussed. In addition, we further delineate the nature of the pharmacophore for this class of compounds, which provides a rational basis for the structure-activity relationships.

Synthesis and cytotoxic evaluation of two novel anthraquinone derivatives

The antitumor activity of dihydroxyanthracenediones such as mitoxantrone on a panel of cancer cell lines during the last 30 years, led investigators to synthesize thousands of anthracycline analogs and test their cytotoxicity to identify compounds superior to the parent drugs in terms of increased therapeutic effectiveness, reduced toxicity or both. To achieve this, new synthesized congeners either have different side arms or have extra rings on their skeletons. Following these studies, we proposed total synthesis of 2-amino-N-[4-(2-amino-3-hydroxy-propionylamino)-9,10-dioxo-9, 10-dihydroanthracene-1-yl]-3-hydroxy-propionamide (V) and 6-amino-hexanoic acid [4-(5-amino-pentanoylamino)-9,10-dioxo-9,10-dihydro-anthracen-1-yl]-amide (VI). Acetylation of 1,4-diaminobenzene using acetyl chloride and reaction with phthalic anhydride under a Friedel-Crafts reaction and then cyclization gave 1, 4-diamino-anthraquinone. This compound was reacted with two amino acids (L-serine and 6-amino hexanoic acid) in their ester forms, using ethyl chloroformate as a coupling agent. Hydrolyzing esterified compounds gave their amino substituted derivatives. These compounds with diamine side arms are supposed to provide better intercalation with DNA. Synthesized novel ametantrone derivatives were tested against a panel of cancer cells (KB, Hela, MDA-MB-468 and K562), using MTT assay. The results showed that tested compounds inhibited the growth of cancer cells at micromolar concentrations. However, compound (VI) was more cytotoxic than compound (V) probably because of its longer side chains and better intercalation with DNA.

EFFECT OF SRUCTURAL FACTORS ON THE FORMATION AND PROPERTIES OF ACYLAMINOANTHRAQUINONES

The N-methyl group prevents the acylation of α-aminoanthraquinones by acetic anhydride in the absence of acid catalysis.This is explained by hindrances for the abstraction of hydrogen atom from the 1-methylamino group, which is connected by an intramolecular hydrogen bond.Acid catalysis levels out the differences in the reactivity of the α-amino and α-methyl amino groups.The α-acetylamino groups have lower hydrolytic stability than the α-N-acetylmethylamino groups.These characteristics make it possible to realize a directed synthesis of acyl derivatives at theprimary or secondary α-amino groups of polyaminoanthraquinones.The introduction of acyl residues into the secondary α-amino groups completely excludes them conjugation with the anthraquinone ring, and an unexpectedly small hypsochromic shift of the absorption is observed in the 4-amino, 4-alkylamino, and particularly the 4-arylamino derivatives of 1-acylaminoanthraquinones.